High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients with Very High HDL Cholesterol and Coronary Disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 6, 2015, Pages 1515-1519

  Agarwala, Anandita P ^a   Rodrigues, Amrith ^a   Risman, Marjorie ^a   McCoy, Mary ^a   Trindade, Kevin ^a   Qu, Liming ^a   Cuchel, Marina ^a   Billheimer, Jeffrey ^a   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

ABC transporters; coronary artery disease; high density lipoprotein cholesterol

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID; PHOSPHOLIPID TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; VERY HIGH DENSITY LIPOPROTEINS;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; EFFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; BLOOD; ESTERIFICATION; MIDDLE AGED;

AGED; CHOLESTEROL; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; ESTERIFICATION; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84933060189     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.305504     Document Type: Article

References (27)

1. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J; Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000. doi: 10.1001/jama.2009.1619.
2. Young CE, Karas RH, Kuvin JT. High-density lipoprotein cholesterol and coronary heart disease. Cardiol Rev. 2004;12:107-119. doi: 10.1097/01. crd.0000097140.29929.8a.
3. Rader DJ, Tall AR. The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Nat Med. 2012;18:1344-1346. doi: 10.1038/nm.2937.
4. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466:707-713. doi: 10.1038/nature09270.
5. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572-580. doi: 10.1016/S0140-6736(12)60312-2.
6. Robinson JG. Dalcetrapib: a review of Phase II data. Expert Opin Investig Drugs. 2010;19:795-805. doi: 10.1517/13543784.2010.488219.
7. Group HTC. Hps2-thrive randomized placebo-controlled trial in 25 673 high-risk patients of er niacin/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. European heart journal. 2013;34:1279-1291
8. Rosenson RS, Brewer HB Jr, Chapman MJ, Fazio S, Hussain MM, Kontush A, Krauss RM, Otvos JD, Remaley AT, Schaefer EJ. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem. 2011;57:392-410. doi: 10.1373/clinchem.2010.155333.
9. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 2009;50 Suppl:S189-S194. doi: 10.1194/jlr. R800088-JLR200.
10. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-135. doi: 10.1056/NEJMoa1001689.
11. Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371:2383-2393. doi: 10.1056/NEJMoa1409065.
12. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via abca1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arteriosclerosis, thrombosis, and vascular biology. 2010;30:796-801
13. Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W, Gao V, Schmitt D, Didonato JA, Fisher EA, Smith JD, Hazen SL. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol. 2013;33:1696-1705. doi: 10.1161/ATVBAHA.113.301373.
14. Hafiane A, Jabor B, Ruel I, Ling J, Genest J. High-density lipoprotein mediated cellular cholesterol efflux in acute coronary syndromes. Am J Cardiol. 2014;113:249-255. doi: 10.1016/j.amjcard.2013.09.006.
15. Shao B, Tang C, Sinha A, Mayer PS, Davenport GD, Brot N, Oda MN, Zhao XQ, Heinecke JW. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ Res. 2014;114:1733-1742. doi: 10.1161/CIRCRESAHA.114.303454.
16. Piperi C, Kalofoutis C, Papaevaggeliou D, Papapanagiotou A, Lekakis J, Kalofoutis A. The significance of serum HDL phospholipid levels in angiographically defined coronary artery disease. Clin Biochem. 2004;37:377-381. doi: 10.1016/j.clinbiochem.2003.10.015.
17. Bellanger N, Orsoni A, Julia Z, Fournier N, Frisdal E, Duchene E, Bruckert E, Carrie A, Bonnefont-Rousselot D, Pirault J, Saint-Charles F, Chapman MJ, Lesnik P, Le Goff W, Guerin M. Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2011;31:1675-1681. doi: 10.1161/ATVBAHA.111.227181.
18. Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC. Highdensity lipoprotein function recent advances. J Am Coll Cardiol. 2005;46:1792-1798. doi: 10.1016/j.jacc.2005.06.080.
19. Ooi EM, Barrett PH, Watts GF. The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: developing a new framework for future therapies. Int J Cardiol. 2013;168:1811-1818. doi: 10.1016/j.ijcard.2013.06.069.
20. Sattler KJ, Elbasan S, Keul P, Elter-Schulz M, Bode C, Gräler MH, Bröcker-Preuss M, Budde T, Erbel R, Heusch G, Levkau B. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol. 2010;105:821-832. doi: 10.1007/s00395-010-0112-5.
21. Fournier N, Paul JL, Atger V, Cogny A, Soni T, de la Llera-Moya M, Rothblat G, Moatti N. HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler Thromb Vasc Biol. 1997;17:2685-2691.
22. Attia N, Nakbi A, Smaoui M, Chaaba R, Moulin P, Hammami S, Hamda KB, Chanussot F, Hammami M. Increased phospholipid transfer protein activity associated with the impaired cellular cholesterol efflux in type 2 diabetic subjects with coronary artery disease. Tohoku J Exp Med. 2007;213:129-137.
23. Kralova Lesna I, Adamkova V, Pagacova L. Effect of rosuvastatin treatment on cholesterol efflux from human macrophages. Neuro Endocrinol Lett. 2011;32 Suppl 2:24-28.
24. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Rosuvastatin blocks advanced glycation end products-elicited reduction of macrophage cholesterol efflux by suppressing NADPH oxidase activity via inhibition of geranylgeranylation of Rac-1. Horm Metab Res. 2011;43:619-624. doi: 10.1055/s-0031-1283148.
25. Shimizu T, Miura S, Tanigawa H, Kuwano T, Zhang B, Uehara Y, Saku K. Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet. Arterioscler Thromb Vasc Biol. 2014;34:2246-2253. doi: 10.1161/ATVBAHA.114.303715.
26. Wang W, Song W, Wang Y, Chen L, Yan X. HMG-CoA reductase inhibitors, simvastatin and atorvastatin, downregulate ABCG1-mediated cholesterol efflux in human macrophages. J Cardiovasc Pharmacol. 2013;62:90-98. doi: 10.1097/FJC.0b013e3182927e7c.
27. Miyamoto-Sasaki M, Yasuda T, Monguchi T, Nakajima H, Mori K, Toh R, Ishida T, Hirata K. Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. J Atheroscler Thromb. 2013;20:708-716.